To identify effective treatments and avoid undesirable effects, an emerging alternative to genotype-based drugs in CF is personalized/precision medicine, i.e., to determine whether rare CFTR mutations respond to existing (or new) CFTR modulators by pre-evaluating them directly on the patient’s tissues ex vivo, which is now also termed theratyping. Here, CFTR is linked to cystic fibrosis.